98%
921
2 minutes
20
Background: End-stage liver disease (ESLD) and heart failure (HF) often coexist and are associated with significant morbidity and mortality. However, the true incidence of HF among patients with ESLD remains understudied.
Objective: This study aims to evaluate the association between ESLD and incident HF in a real-world clinical cohort.
Design And Participants: A retrospective electronic health records database analysis of individuals with ESLD and frequency-matched controls without ESLD in a large integrated health system.
Main Measures: The primary outcome was incident HF, which was defined by the International Classification of Disease codes and manually adjudicated by physician reviewers. The Kaplan-Meier method was used to estimate the cumulative incidence of HF. Multivariate proportional hazards models adjusted for shared metabolic factors (diabetes, hypertension, chronic kidney disease, coronary heart disease, body mass index) were used to compare the risk of HF in patients with and without ESLD.
Key Results: Of 5004 patients (2502 with ESLD and 2502 without ESLD), the median (Q1-Q3) age was 57.0 (55.0-65.0) years, 59% were male, and 18% had diabetes. Over a median (Q1-Q3) follow-up of 2.3 (0.6-6.0) years, 121 incident HF cases occurred. Risk for incident HF was significantly higher for patients with ESLD compared with the non-ESLD group (adjusted HR: 4.67; 95% CI: 2.82-7.75; p < 0.001), with the majority of the ESLD group (70.7%) having HF with preserved ejection fraction (ejection fraction ≥ 50%).
Conclusion: ESLD was significantly associated with a higher risk of incident HF, independent of shared metabolic risk factors, with the predominant phenotype being HF with preserved ejection fraction.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10465455 | PMC |
http://dx.doi.org/10.1007/s11606-023-08199-z | DOI Listing |
J Clin Lab Anal
September 2025
Department of Laboratory Medicine, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.
Background: Hepatocellular carcinoma (HCC) patients who underwent transarterial chemoembolization (TACE) have heterogeneous clinical outcomes. Accurate prognosis prediction and risk stratification are crucial for individualized treatment. We sought to develop a novel prognostic model for overall survival (OS) that incorporated contemporary clinical and laboratory factors for estimating individual prognosis.
View Article and Find Full Text PDFCell Mol Gastroenterol Hepatol
September 2025
Hepatobiliary Center, the First Affiliated Hospital with Nanjing Medical University; Research Unit of Liver Transplantation and Transplant Immunology, Chinese Academy of Medical Sciences; Nanjing, Jiangsu Province, China; Department of General Surgery, the Affiliated Hospital of Xuzhou Medical Unive
Background & Aims: Liver fibrosis is characterized by sustained injury stress, chronic inflammation, and repeated cell death and repair, all of which promote the progression of end-stage liver diseases (e.g., liver cirrhosis and carcinoma).
View Article and Find Full Text PDFWorld J Gastroenterol
August 2025
Department of Infectious Diseases, The Hebei Medical University Third Hospital, Shijiazhuang 050000, Hebei Province, China.
Background: Acute-on-chronic liver failure (ACLF) is characterized by severe metabolic disturbances; however, the specific metabolomic features and their predictive value on 90-day prognosis remain unclear.
Aim: To identify serum metabolomic changes in patients with ACLF with different prognoses to support clinical prediction of outcomes and treatment decisions.
Methods: This non-interventional, observational case-control study enrolled 58 patients with ACLF.
Nephrology (Carlton)
September 2025
Department of Medical Microbiology & Immunology, University of Alberta, Edmonton, Alberta, Canada.
Microsporidia are emerging opportunistic pathogens in immunosuppressed individuals, including solid organ transplant recipients. We present a case of tubulointerstitial nephritis (TIN) caused by Microsporidia infection in a 55-year-old male who underwent combined liver-kidney transplantation (CLKT) for metabolic-associated fatty liver disease and end-stage kidney disease. The patient developed diarrhoea, abdominal bloating and acute kidney injury (AKI) 1 month post-transplant.
View Article and Find Full Text PDFInfect Dis Ther
September 2025
The Third Clinical Medical College, Qingdao University School of Medicine, Qingdao Municipal Hospital, Qingdao, Shandong, China.
Introduction: Oral nucleos(t)ide analogues (NAs) are widely used in managing hepatitis B virus-associated acute-on-chronic liver failure (HBV-ACLF). Among first-line therapies, entecavir (ETV), tenofovir disoproxil fumarate (TDF), and tenofovir alafenamide (TAF) are commonly prescribed. However, their comparative efficacy and safety remain unclear in HBV-ACLF.
View Article and Find Full Text PDF